Oxygenta Pharmaceutical (524636) Q4 25/26 earnings summary

Executive summary

• Audited financial results for the quarter and year ended March 31, 2026, were approved, showing continued losses but some operational improvements year-over-year.

• Board approved appointments of two new directors and a new internal auditor, and authorized steps for the upcoming AGM.

• Statutory auditors issued an unmodified opinion on the financial statements.

Financial highlights

• Revenue from operations for FY26 was ₹11,298.19 lakhs, up from ₹10,929.86 lakhs in FY25.

• Net loss for FY26 was ₹1,704.63 lakhs, compared to a net loss of ₹1,040.55 lakhs in FY25.

• Q4 FY26 revenue was ₹4,961.40 lakhs, nearly flat compared to Q4 FY25 at ₹4,946.66 lakhs.

• Loss before tax for Q4 FY26 was ₹127.97 lakhs, an improvement from ₹379.93 lakhs loss in Q4 FY25.

• Basic and diluted EPS for FY26 stood at ₹(4.75), down from ₹(2.86) in FY25.

Outlook and guidance

• The company is prioritizing compliance and transparency, especially regarding MSME creditor identification and bill-to-bill adjustments.

• Focus remains on operational improvements and addressing outstanding reporting issues.